Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: Results of a randomized, double-blind phase III trial

Annals of Oncology

Volumn 27, Issue 1, 2016, Pages 172-178

  Weinstein, Cindy L J ^a   Jordan, K ^b   Green, S A ^a   Camacho, E ^c   Khanani, S ^d   Beckford Brathwaite, E ^a   Vallejos, W ^a   Liang, L W ^a   Noga, S J ^e   Rapoport, B L ^f  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c DESERT REGIONAL MEDICAL CENTER   (United States)

^d Reliant Medical Group Inc   (United States)

^e Weinberg Cancer Institute   (United States)

^f Medical Oncology Center of Rosebank   (South Africa)

Author keywords

Fosaprepitant dimeglumine; Moderately emetogenic chemotherapy; Nausea; Neurokinin 1 receptor antagonists; Vomiting

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; FOSAPREPITANT; ONDANSETRON; OXALIPLATIN; PLACEBO; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; MORPHOLINE DERIVATIVE;

ADULT; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESEARCH; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HUMAN; INJECTION SITE PHLEBITIS; MAJOR CLINICAL STUDY; MALE; MODERATELY EMETOGENIC CHEMOTHERAPY; MULTICENTER STUDY; NEOPLASM; NEUTROPENIA; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOPHLEBITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; CHEMICALLY INDUCED; CLINICAL TRIAL; LUNG NEOPLASMS; MIDDLE AGED; NAUSEA; VOMITING;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MORPHOLINES; NAUSEA; TREATMENT OUTCOME; VOMITING;

EID: 84960124012     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv482     Document Type: Article

References (22)

1. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21(suppl 5): v232-v243.
2. National Comprehensive Cancer Network, Inc. NCCN Clinical Practice Guidelines in Oncology. Antiemesis. Version 1.2014. National Comprehensive Cancer Network Web site; 2014.
3. Gralla RJ, Roila F, Tonato M, Herrstedt J. MASCC/ESMO antiemetic guideline 2013. Hillerød, Denmark: Multinational Association of Supportive Care in Cancer 2014.
4. Jordan K, Gralla R, Jahn F, Molassiotis A. International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. Eur J Pharmacol 2014; 722: 197-202.
5. Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29: 4189-4198.
6. Hickok JT, Roscoe JA, Morrow GR et al. 5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial. Lancet Oncol 2005; 6: 765-772.
7. Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 2005; 23: 1289-1294.
8. Hesketh PJ, Grunberg SM, Gralla RJ et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21: 4112-4119.
9. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090-3098.
10. Warr DG, Hesketh PJ, Gralla RJ et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005; 23: 2822-2830.
11. Prescribing information. Emend (Aprepitant) Capsules, for Oral use. Whitehouse Station, NJ: Merck Sharp & Dohme Corp. 2013.
12. Prescribing information. Emend (Fosaprepitant Dimeglumine) for Injection, for Intravenous use. Whitehouse Station, NJ: Merck Sharp & Dohme Corp. 2013.
13. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 2015; 26: 1081-1090.
14. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997; 15: 103-109.
15. Saito H, Yoshizawa H, Yoshimori K et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol 2013; 24: 1067-1073.
16. Gralla RJ, de Wit R, Herrstedt J et al. Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin: analysis of combined data from two phase III randomized clinical trials. Cancer 2005; 104: 864-868.
17. Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, doubleblind study. Support Care Cancer 2010; 18: 423-431.
18. Aapro M, Rugo H, Rossi G et al. A randomized phase 3 study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25: 1328-1333.
19. Schnadig ID, Modiano MR, Poma A et al. Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC). J Clin Oncol 2014; 32(5 suppl): abstr 9633.
20. Grunberg S, Chua D, Maru A et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 2011; 29: 1495-1501.
21. Gralla RJ, Bosnjak SM, Hontsa A et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 2014; 25: 1333-1349.
22. Leal AD, Kadakia KC, Looker S et al. Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer 2014; 22: 1313-1317.